The continuous HIV-1 recombination forms circulating in China poses a persistent challenge to epidemic control. And this study identifies two novel unique recombinant forms (URFs), BDNY017 and BDK025, from antiretroviral therapy (ART)-failing patients in Hebei Province. Near full-length genomic analysis revealed that BDNY017 is a triple mosaic of CRF08_BC, CRF07_BC, and subtype B, whereas BDK025 is a dual recombinant of CRF07_BC and CRF08_BC. Genotypic resistance testing further uncovered M184V, A98G, and E138K mutations in BDNY017, while BDK025 carried no major pol-region resistance mutations. Notably, the report of CRF08_BC-involved URFs in northern China, expanding the known geographic distribution of such recombinants beyond their traditional southwestern focus and underscoring the urgent need for enhanced molecular surveillance, particularly among ART-failing individuals, to track emerging recombinants and assess their potential impact on treatment outcomes and transmission dynamics.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: